166 related articles for article (PubMed ID: 16809156)
1. Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature.
Brandes JC; Grossman SA; Ahmad H
Cancer Invest; 2006; 24(3):283-7. PubMed ID: 16809156
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
6. FDA drug approval summaries: pemetrexed (Alimta).
Hazarika M; White RM; Johnson JR; Pazdur R
Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
[TBL] [Abstract][Full Text] [Related]
9. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer.
Bosch-Barrera J; Gaztañaga M; Ceballos J; Pérez-Gracia JL; López-Picazo JM; García-Foncillas J; Ferrer M; Sanz ML; Pretel M; Idoate MA; Gil-Bazo I
Onkologie; 2009 Oct; 32(10):580-4. PubMed ID: 19816075
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
Adjei AA
Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed therapy for malignant pleural mesothelioma.
Puto K; Garey JS
Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed-cisplatin combination in mesothelioma.
Reck M; Gatzemeier U
Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
Budde LS; Hanna NH
Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
[TBL] [Abstract][Full Text] [Related]
15. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
Li L; Razak AR; Hughes A
Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
18. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
[TBL] [Abstract][Full Text] [Related]
19. Radiation recall dermatitis with pemetrexed.
Hureaux J; Le Guen Y; Tuchais C; Savary L; Urban T
Lung Cancer; 2005 Nov; 50(2):255-8. PubMed ID: 16111784
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
Villela LR; Stanford BL; Shah SR
Pharmacotherapy; 2006 May; 26(5):641-54. PubMed ID: 16637794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]